CAT
Caterpillar Inc.
CAT's fundamentals are strong, but it looks expensive: trading at 24x earnings, above its usual 18x. Analysts expect strong earnings growth, though they disagree widely on how much.
DCM
Universal Safety Products, Inc.
There isn't enough reported data to score DCM yet.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
DCM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Weak |
DCM's revenue, profitability, cash flow and balance sheet are all currently weak.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
DCM PE Valuation
DCM has no meaningful PE right now: it lost money over the past year.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
DCM Forward outlook
There aren't enough analyst estimates for DCM to show an outlook.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $29.73 | +17% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over DCM on earnings quality, reporting a profit while its opponent remains loss making.
DCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.05 | -272% |
| Q1 2026 | -$1.04 | -573% |
| Q4 2025 | -$0.08 | +$0.46 |
| Q3 2025 | $0.51 | +$0.61 |
| Q2 2025 | $1.19 | +$1.62 |
| Q1 2025 | $0.22 | +$0.39 |
| Q4 2024 | -$0.54 | -460% |
| Q3 2024 | -$0.10 | -138% |
DCM has swung to a loss: it lost $2.05 per share over the past year, after a profit the year before.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over DCM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over DCM on profitability, with a higher operating margin.
DCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $109.6K | -97% |
| Q1 2026 | $240.4K | -96% |
| Q4 2025 | $22.5K | -100% |
| Q3 2025 | $760K | -89% |
| Q2 2025 | $3.8M | -17% |
| Q1 2025 | $6.2M | +29% |
| Q4 2024 | $5.5M | +19% |
| Q3 2024 | $7.2M | +94% |
DCM's revenue has slid since its 2024 peak: $109,559 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -673% | -659 points |
| Q1 2026 | -419% | -435 points |
| Q4 2025 | -9700% | -9685 points |
| Q3 2025 | -122% | -132 points |
| Q2 2025 | -14% | -5.3 points |
| Q1 2025 | 16% | +25 points |
| Q4 2024 | -16% | -18 points |
| Q3 2024 | 9.4% | +14 points |
DCM's operating margin was −673% last quarter, down 659 points from the same quarter a year ago, near the bottom of its range since 2019.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the edge over DCM on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$733.2K | -127% |
| Q1 2026 | -$811.4K | -$499.8K |
| Q4 2025 | -$2.6M | -202% |
| Q3 2025 | $1.2M | +$3.3M |
| Q2 2025 | $2.8M | +$4M |
| Q1 2025 | -$311.6K | -182% |
| Q4 2024 | $2.5M | +$3M |
| Q3 2024 | -$2.1M | -541% |
DCM's free cash flow was −$3M over the past year, against $3M the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over DCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
DCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +624K shares |
| 1 year | +27% | +624K shares |
| 3 years | +27% | +624K shares |
| 5 years | +27% | +624K shares |
| Available history | +27% | +624K shares |
DCM has 3M diluted shares, up 27% from a year ago.
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
DCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | 4.3x | High |
| Q4 2023 | 4.3x | High |
| Q3 2023 | 1.9x | Healthy |
| Q2 2023 | 2.0x | Healthy |
| Q1 2023 | 1.3x | Healthy |
| Q4 2022 | -0.2x | Net Cash |
| Q3 2022 | -0.5x | Net Cash |
| Q2 2022 | -26.9x | Net Cash |
DCM's net debt is about 4.3 years of its operating earnings (EBITDA), up from 1.3 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
DCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 5.7 | Oversold |
DCM's weekly RSI is 37 (neutral) and its Stochastic is 6 (oversold).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.1% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
DCM PE vs Industrials Sector
| Metric | DCM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
DCM has no meaningful PE right now: it lost money over the past year.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has the edge over DCM on trend strength, trading above more of its moving averages.
DCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.16 | 27% below |
| 20 week MA | $4.32 | 30% below |
| 50 week MA | $5.02 | 40% below |
| 100 week MA | $4.10 | 26% below |
| 200 week MA | $3.05 | 0.7% below |
DCM is in a downtrend: it's below all five of its weekly moving averages, and 0.7% below its 200-week average.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over DCM on returns for 2026, with the stronger performance.
DCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.61 | $2.91 | +377% |
| 2021 | $2.91 | $3.64 | +25% |
| 2022 | $3.64 | $2.10 | -42% |
| 2023 | $2.10 | $1.66 | -21% |
| 2024 | $1.66 | $2.31 | +39% |
| 2025 | $2.31 | $5.00 | +116% |
| 2026 YTD | $5.00 | $3.03 | -39% |
DCM's yearly returns have swung widely, from +377% in 2020 to −42% in 2022. It's down 39% so far in 2026.